secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000805928-24-000135
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q3 revenue $48.6M (+18% YoY), adjusted net income $3.1M; BLA accepted by FDA
--------------------------------------------------------------------------------

- Revenue $48.6M (+17.9% YoY); gross margin 74.9% vs 76.8% in prior year.
- Net loss $1.9M ($0.04/shr) vs $4.1M ($0.10/shr); adjusted net income $3.1M ($0.07/shr).
- Adjusted EBITDA $6.5M vs $2.4M in Q3 2023; cash $30.5M at quarter end.
- FDA accepted BLA for Avance Nerve Graft under standard review; PDUFA date Sept 5, 2025; no advisory committee planned.
- 2024 revenue guidance reaffirmed $182M-$186M; expects high end of gross margin range and cumulative net cash flow positive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000135/0000805928-24-000135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000135/axgn-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000805928-24-000135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer